UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1328-7
Program Prior Authorization/Notification
Medication Evrysdi® (risdiplam)
P&T Approval Date 9/2020, 9/2021, 7/2022, 8/2023, 7/2024, 12/2024, 4/2025
Effective Date 6/1/2025
1. Background:
Evrysdi is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of
spinal muscular atrophy (SMA) in pediatric and adult patients.
2. Coverage Criteriaa:
A. Initial Authorization
1. Evrysdi will be approved based on all of the following criteria:
a. Diagnosis of spinal muscular atrophy (SMA)
-AND-
b. Patient is not receiving concomitant chronic survival motor neuron (SMN) modifying
therapy [e.g., Spinraza (nusinersen)]
-AND-
c. One of the following:
(1) Patient has not previously received gene replacement therapy for the treatment of
SMA [e.g., Zolgensma (onasemnogene abeparvovec-xioi)]
-OR-
(2) Both of the following:
(a) Patient has previously received gene replacement therapy [e.g., Zolgensma
(onasemnogene abeparvovec-xioi)] for the treatment of SMA
-AND-
(b) Submission of medical records (e.g., chart notes, laboratory values) documenting
a clinically meaningful functional decline (e.g., loss of motor milestone) since
receiving gene replacement therapy [e.g., Zolgensma (onasemnogene
abeparvovec-xioi)]
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
1
B. Reauthorization
1. Evrysdi will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Evrysdi therapy
-AND-
b. Patient is not receiving concomitant chronic survival motor neuron (SMN) modifying
therapy [e.g., Spinraza (nusinersen)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Medical Necessity and/or Supply limits may be in place.
4. References:
1. Evrysdi [package insert]. South San Francisco, CA: Genentech, Inc; September 2024.
Program Prior Authorization/Notification – Evrysdi (risdiplam)
Change Control
9/2020 New program
9/2021 Annual review with no changes to clinical coverage criteria. Updated
reference.
7/2022 Updated criteria to align with new labeled indication in patients of all
ages. Added state mandate and updated reference.
8/2023 Annual review. Updated reference.
7/2024 Annual review. Updated reference.
12/2024 Added criteria for patients that have documented decline from
pretreatment baseline status following administration of gene
replacement therapy. Updated reference.
4/2025 Revised criteria for patients that have documented decline from
pretreatment baseline status following administration of gene
replacement therapy.
© 2025 UnitedHealthcare Services, Inc.
2